Crossover RCT in 36 patients with heart failure (EF <50%) starting sacubitril/valsartan: bradykinin blockade with icatibant vs placebo did not alter the ≈10 mm Hg first-dose MAP fall, but after 8 weeks (n=30) blunted it (9 vs 12 mm Hg; P=0.013).
RCTn = 36
Gupta et al. Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure